Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI.

Alphabet-owned Isomorphic Labs says its first AI-designed drug is nearly ready for human trials, targeting diseases like cancer and heart failure. Nucleus_AI 2802 Stories Tuesday July 08, 2025 , 2 ...

Google DeepMind’s spin-off Isomorphic Labs says it’s almost ready to begin human testing for AI-designed drugs. Built on the success of AlphaFold, the company aims to speed up drug development in ...

Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg News reported, citing the company's CEO Demis Hassabis.

A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But can we trust drugs designed by a mind that isn't human?

Founder and Chief Executive Officer Demis Hassabis, who also leads Deepmind, suggested in January that Isomorphic Labs will have AI-designed drugs in clinical trials by the end of 2025.

Expect AI-made prescription drugs to be ready for clinical trials in a couple of years, predicts Google DeepMind CEO 35,048 people played the daily Crossword recently. Can you solve it faster than ...

Google Cloud joins with biotech startups to accelerate AI-driven drug discovery and scientific research - SiliconANGLESiliconANGLE Media is a recognized leader in digital media innovation serving ...

After years of development, Murdoch says human clinical trials for Isomorphic’s AI-designed drugs are finally within reach.

Expect AI-made prescription drugs to be ready for clinical trials in a couple of years, predicts Google DeepMind CEO By Sarah Jackson Andrew Brookes/Getty Images Feb 26, 2024, 1:11 PM PT ...

A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as ...